FOLD – amicus therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Amicus Therapeutics, Inc. (NASDAQ: FOLD) was upgraded by analysts at Guggenheim from a "neutral" rating to a "buy" rating. They now have a $13.00 price target on the stock.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target lowered by analysts at UBS Group AG from $20.00 to $19.00. They now have a "buy" rating on the stock.
Amicus (FOLD) Q1 Earnings Top, Sales Lag, '24 Outlook Updated [Yahoo! Finance]
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target lowered by analysts at Morgan Stanley from $20.00 to $19.00. They now have an "overweight" rating on the stock.
Form 10-Q AMICUS THERAPEUTICS, For: Mar 31
Form 8-K AMICUS THERAPEUTICS, For: May 09
Form 4 AMICUS THERAPEUTICS, For: May 01 Filed by: Campbell Bradley L
Form 144 AMICUS THERAPEUTICS, Filed by: Campbell Bradley L
Form ARS AMICUS THERAPEUTICS, For: Dec 31
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.